Lantheus Hosts Inaugural Investor Day
May 16 2022 - 4:30PM
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), will host
its Inaugural Investor Day at the Nasdaq MarketSite on Tuesday, May
17, beginning at 9:00 a.m. EDT. Members of Lantheus’ management
team will provide updates on the company’s long-term vision for
growth, key commercial products, development assets and financial
strategy.
“We are excited to host our Inaugural Investor Day to provide
the investment community with a deeper understanding of our
business and growth strategies to deliver long-term value to
patients, customers, and shareholders,” said Mary Anne Heino,
President and CEO.
The live webcast will begin at 9:00 a.m. EDT and conclude at
approximately 12:15 p.m. The presentations and webcast can be
accessed from at https://investorday.lantheus.com and will be
available for replay following the event.
About Lantheus Holdings, Inc. Lantheus
Holdings, Inc. is the parent company of Lantheus Medical
Imaging, Inc., Progenics Pharmaceuticals,
Inc. and EXINI Diagnostics AB and an established
leader and fully integrated provider committed to innovative
imaging diagnostics, targeted therapeutics and artificial
intelligence solutions to Find Fight and Follow® serious medical
conditions. Lantheus provides a broad portfolio of products,
including the echocardiography agent DEFINITY® Vial for
(Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY®, a
PSMA PET imaging agent for the detection of suspected recurrent or
metastatic prostate cancer; PYLARIFY AI™, an artificial
intelligence platform that assists in the evaluation of PSMA PET
images; TechneLite® (Technetium Tc99m Generator), a
technetium-based generator that provides the essential medical
isotope used in nuclear medicine procedures; AZEDRA® for the
treatment of certain rare neuroendocrine tumors; and
RELISTOR® for the treatment of opioid-induced constipation,
which is partnered with Bausch Health Companies, Inc. The Company
is headquartered in North Billerica, Massachusetts with
offices in New Jersey, Canada and Sweden. For
more information, visit www.lantheus.com.
Safe Harbor for Forward-Looking and Cautionary
StatementsThis press release contains “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, that are subject to risks and
uncertainties and are made pursuant to the safe harbor provisions
of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements may be identified by their use of terms
such as “deliver,” “introducing,” “position,” “provide,” “will” and
other similar terms. Such forward-looking statements are based upon
current plans, estimates and expectations that are subject to risks
and uncertainties that could cause actual results to materially
differ from those described in the forward-looking statements. The
inclusion of forward-looking statements should not be regarded as a
representation that such plans, estimates and expectations will be
achieved. Readers are cautioned not to place undue reliance on the
forward-looking statements contained herein, which speak only as of
the date hereof. The Company undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new
information, future developments or otherwise, except as may be
required by law. Risks and uncertainties that could cause our
actual results to materially differ from those described in the
forward-looking statements are discussed in our filings with the
Securities and Exchange Commission (including those described in
the Risk Factors section in our Annual Reports on Form 10-K and our
Quarterly Reports on Form 10-Q).
Contacts:Mark KinarneySenior Director, Investor
Relations978-671-8842ir@lantheus.com
Melissa Downs Senior Director, Corporate
Communications646-975-2533media@lantheus.com
Lantheus (NASDAQ:LNTH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lantheus (NASDAQ:LNTH)
Historical Stock Chart
From Apr 2023 to Apr 2024